


La Cámara de Comercio de Puerto Rico y su Comité de Salud presentan el Foro:



One of my greatest priorities is to reduce the price of prescription drugs. In many other countries, these drugs cost far less than what we pay in the United States. That is why I have directed my Administration to make fixing the injustice of high drug prices one of our top priorities. Prices will come down."

- President Donald J. Trump



- American Patients First at a glance
 - Four challenges
 - High List Prices
 - Government Programs and seniors overpaying for lack of negotiation tools
 - High & Rising out of pocket costs for consumers
 - Foreign governments free-riding off of American Investment in Innovation
 - Four Key Strategies for Reform
 - Improved competition
 - Better Negotiation
 - Incentives for lower list prices
 - Lowering out of pocket costs






FIGURE 3

List Price vs. Net Price

SOURCE

Medicine Use and Spending in the U.S.; A Review of 2017 and Outlook to 2022. April 19, 2018



- Increase competition
 - Immediate Actions
 - Proposals to stop Medicaid and ACA programs from raising prices in the private sector
 - Further Opportunities
 - Promote use of biosimilars
- Better Negotiation
 - Further Opportunities
 - Give more negotiating power to Medicare Part D plan sponsors



- Incentive for Lowering List Prices
 - Further Opportunities
 - Measures to restrict the use of rebates (Safe Harbor under Anti-Kickback statute)
 - Additional reforms to the rebating system
 - Considering fiduciary status for PBMs
 - Reform the Medicaid Drug Rebate Program
 - Reforms to the 340B Drug Discount Program





Gracias

Síguenos en: (f) (in) (P) (III)











www.camarapr.org

#tucamaraenaccion